Modality
Gene Therapy
MOA
SOS1i
Target
Aβ
Pathway
Proteasome
NBMCCPsoriasis
Development Pipeline
Preclinical
Jan 2025
→ Oct 2027
PreclinicalCurrent
NCT08357509
539 pts·NB
2025-01→2027-10·Terminated
539 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-251.6y awayInterim· NB
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2027-10-25 · 1.6y away
NB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08357509 | Preclinical | NB | Terminated | 539 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 |